Advertisement

Topics

Cilag AG Company Profile

16:09 EST 11th December 2018 | BioPortfolio

Nil

Location

Hochstrasse 201
Schaffhausen
Schweiz
8205
Switzerland

Contact

Phone: 41 (52) 630 9111
Fax: 41 (52) 630 9444
Email: cilag@cilch.jnj.com


News Articles [16 Associated News Articles listed on BioPortfolio]

Janssen affiliate Cilag and Argenx sign deal for cancer therapy

Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab...Read More... The post Janssen aff...

J&J/Janssen’s Cilag to Co-Develop argenx’s Cusatuzumab in $1.8B+ Collaboration

Cilag International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, will partner with argenx to develop its cancer-fighting antibody cusatuzumab (ARGX-110), through a c...

Cilag and Argenx in Cancer Drug Pact

Swiss-based Cilag, an affiliate of Janssen, the pharmaceuticals division of Johnson & Johnson, has entered into a global collaboration and license agreement with biotech company argenx to develop ...

Cilag gets global rights to argenx's cusatuzumab

Argenx SE licensed Janssen’s Cilag GMBH International exclusive global rights to its cusatuzumab (ARGX110) in blood cancers.

Cilag collaborates with argenx to develop and commercialise cancer immunotherapy cusatuzumab

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to...

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement ...

ZUG, Switzerland, December 3, 2018 /PRNewswire/ -- Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has Read more...

$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX https://www.prnewswire.com/news-releases/janssen-affiliate-cilag-gmbh-international-enters-worldwide-collabo

$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX

Cusatuzumab to be developed for #leukemia, MDS under $1.8B+ collaboration by J&J / @JanssenGlobal's Cilag and argenx ($ARGX): http://ow.ly/140N30mQtbF 

Cusatuzumab to be developed for #leukemia, MDS under $1.8B+ collaboration by J&J / @JanssenGlobal's Cilag and argenx ($ARGX): http://ow.ly/140N30mQtbF 

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Stelara [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA (ustekinumab) Injection, for subcutaneous useIn...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.

Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III ...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia ...

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering ...

Action of the Vidaza on the Atrial Fibrillation

Genomic studies on atrial fibrillation patients have identified polymorphisms in regions surrounding the PITX2 gene, suggesting it could be the locus responsible for atrial fibrillation. T...

Companies [7 Associated Companies listed on BioPortfolio]

Janssen-Cilag EMEA, EMHF, ESHA & ISG

Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V., is a research-based pharmaceutical company that develops and markets innovative, high-quality pharmaceutical products and services aim...

Cilag AG

Nil

Janssen-Cilag AG

NIL

Janssen-Cilag Farmacéutica

NIL

Janssen-Cilag International NV

More Information about "Cilag AG" on BioPortfolio

We have published hundreds of Cilag AG news stories on BioPortfolio along with dozens of Cilag AG Clinical Trials and PubMed Articles about Cilag AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cilag AG Companies in our database. You can also find out about relevant Cilag AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record